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SummAry – Amyotrophic lateral sclerosis (AlS) is a neurodegenerative disease. Data from 
the literature show that systemic immune activation plays a role in AlS. OX40 (CD134) is member 
of the tumor necrosis factor  receptor family and is expressed selectively on activated t lymphocytes. 
The aim of the study was to measure serum soluble OX40 (sOX40) levels in patients with AlS. The 
study included 25 AlS patients and 15 control subjects. Serum sOX40 levels were determined by 
the enzyme-linked immunosorbent method. Study showed that sOX40 levels were significantly 
decreased in serum of AlS patients compared with controls (p=0.05). There was no significant 
correlation between serum sOX40 levels and clinical parameters of AlS such as severity of the AlS 
patient clinical state and duration of the disease (p>0.05). in conclusion, decrease in serum sOX40 
levels in patients with AlS suggests that this cytokine may be implicated in the pathomechanisms 
of this disease. 
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Introduction
Data from the literature show that systemic im-
mune activation plays a role in amyotrophic lateral 
sclerosis (AlS)1. According to Alexianu et al.2, the 
up-regulation of proinflammatory factors during early 
presymptomatic stages as well as the expansion of im-
mune activation as the disease progresses in mutant 
SOD transgenic mice, an animal model of AlS, sug-
gest that immune-inflammatory mechanisms could 
contribute to the disease progression.
OX40 (CD134) is member of the tumor necrosis 
factor (tnF) receptor family and is expressed selec-
tively on activated t lymphocytes. The interaction with 
OX40 ligand (OX40 l) delivers costimulatory signals 
to t cells3. This cytokine regulates survival and func-
tions of depletion-resistant t cells4. it is known that t 
cells play an important role during inflammation5.
The OX40/OX40 l interaction induces auto-
immune-like diseases6. blockade of the interaction 
between OX40 and OX40 l inhibited immune re-
sponses in both mouse and nonhuman primate mod-
els of allergic inflammation7. According to tateyama 
et al.8 OX40 is expressed on activated t cells, which 
may play an important role in autoimmune diseases 
such as polymyositis and granulomatous myopathy. A 
study conducted by Xiaoyan et al.9 showed that freshly 
isolated CD4+ t-cells from patients with myasthe-
nia gravis expressed OX40 to a greater extent than 
cells from healthy individuals. moreover, CD134 is 
up-regulated in the central nervous system (CnS) of 
patients with multiple sclerosis10. OX40 may have a 
proinflammatory function during immune activation 
and is expressed on a variety of leukocytes within the 
body11. The OX40 receptor is expressed on autoreactive 
CD4+ t cells isolated from the site of inflammation 
in rats with clinical signs of experimental autoimmune 
encephalomyelitis12. OX40 can also control prolifera-
tion, survival, and production of cytokines13,14. 
The aim of the study was to measure soluble OX40 
(sOX40) levels in serum samples from patients with 
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AlS and to investigate whether there is a relation-
ship between the concentration of sOX40 and clinical 
parameters of the disease.
Material and Methods
twenty-five (14 male/11 female) AlS patients 
(average age 57, range 34-74 years) were diagnosed 
according to the el escorial criteria of AlS15. The 
clinical condition of patients was measured by the 
Amyotrophic lateral Sclerosis Functional rating 
Scale (AlSFrS)16. According to this scale, AlS pa-
tients scored from 8 to 36 points and were divided 
into two subgroups: those with a mild clinical state 
(over 25 points), 15 patients; and those with a severe 
clinical state (up to 25 points), 10 patients. The aver-
age duration of the disease was 16 months (3 months 
to 8 years). The AlS patients were also divided into 
two subgroups according to the duration of AlS (14 
patients with short duration ≤12 months/11 patients 
with long duration >12 months) and according to type 
of AlS onset (15 patients with limb-onset/10 patients 
with bulbar-onset). 
The age-matched control group consisted of 15 (8 
male/7 female) patients with lumbosacral disk disease. 
The study was approved by the medical university 
ethics Committee and performed in accordance with 
the ethical standards established in helsinki. 
Serum samples from AlS patients and control 
subjects were collected into plastic tubes and centri-
fuged rapidly. The samples were stored at -70 ºC until 
analysis. The sOX40 levels were measured by the en-
zyme-linked immunosorbent method aided commer-
cial eliSA kit for human sCD134 (OX40) (bender 
medSystems Diagnostics Gmbh, Vienna, Austria) in 
accordance with the manufacturer’s instructions. 
On statistical analysis, nonparametric mann-
whitney rank sum test was used to examine differ-
ences between the groups. Correlation analysis was 
performed by using Spearman rank correlation. The 
values were expressed in pg/ml, as median and range. 
p values ≤0.05 were considered significant.
Results
Study results showed that serum sOX40 levels 
were significantly decreased in the overall AlS pa-
tient group compared with controls (p=0.05). The 
sOX40 levels were also significantly decreased in pa-
tients with bulbar onset of AlS compared to controls 
(p=0.02). There were no significant differences in 
serum sOX40 levels between the subgroups of AlS 
patients according to their clinical state, type of AlS 
onset and disease duration (p>0.05). The median val-
ues of serum sOX40 levels and comparative analysis 
between subgroups are presented in table 1. 
Discussion
Data from the literature show that chronic inflam-
mation is associated with neurodegenerative diseases, 
Table 1. Serum soluble OX40 (sOX40) levels and comparative between-group analysis
        Group                          sOX40 level (pg/ml)
                                                 median (range) Comparison
Control                                  1300  (747-1607) Control vs. AlS total
                 p=0.05*AlS – total                            1149  (464-1711)
AlS – short duration             1119 (464-1711) AlS short vs. long duration
                 p=0.44      AlS – long duration              1241 (622-1412) 
AlS – bulbar onset                1129 (471-1458) AlS bulbar vs. limb onset 
                p=0.29AlS – limb onset                   1241 (464-1711)
AlS - mild clinical state        1129  (464-1711) AlS mild vs. severe clinical state
                 p=0.56AlS – severe clinical state     1231  (622-1458)
Data are expressed as median and range; AlS = amyotrophic lateral sclerosis; *statistical significance P≤0.05; 
mann-whitney rank sum test
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including AlS17,18. Zhang et al.19 observed activated 
monocyte/macrophages in serum of patients with 
AlS and their activation was related to the rate of 
AlS disease progression. immunohistochemical 
studies demonstrated the presence of t-cell lympho-
cytes in the spinal cord of AlS patients. According to 
engelhardt et al.20, t-helper cells were observed in the 
proximity to corticospinal tract degeneration, while 
t-helper and t-suppressor cytotoxic cells were found 
in ventral horns. Graves et al.21 revealed the inflam-
mation in AlS spinal cord and brain to be mediated 
by activated macrophages, mast cells and t cells.
holmoy states that the inflammatory process in 
AlS involves infiltration of t cells and activation of 
antigen presenting cells co-localizing with motor neu-
ron damage in the brain and spinal cord22. The role 
of t cells in this process is unclear. Probably, t cells 
may damage motor neurons by the cell-cell contact or 
cytokine secretion, or contribute indirectly to motor 
neuron damage through activation of microglia and 
macrophages. it cannot be excluded that t cell infiltra-
tion may be secondary process to the death of motor 
neurons. On the other hand, there is evidence that t 
cell responses may play a neuroprotective role in AlS. 
Shi et al.23 observed a significant positive correla-
tion of t cell percentage with the AlS progression 
rate. A systemic low-grade inflammation was detected 
in patients with AlS and was correlated with their de-
gree of disability24. moreover, elevation of inflamma-
tory markers such as tnF-alpha, interferon-gamma 
(iFn-γ) and nitric oxide was demonstrated in serum 
of AlS patients compared to normal controls25.
According to troost et al.26, the majority of many 
diffusely scattered lymphocytes seen in the anterior 
and lateral corticospinal tracts and anterior horns be-
longed to the suppressor/cytotoxicity t cell subset. 
The circulating autoreactive lymphocytes of patients 
with AlS were isolated and activated in vitro. it was 
observed that autoreactive cells may induce differen-
tiation of mesenchymal stem cells to neuronal stem 
cells and this is a protective physiologic mechanism to 
nerve tissue repair27.
it was observed that t cell-dependent immunity 
in the CnS is beneficial for neuroprotection and neu-
rogenesis. The expression of OX40 l in microglia 
provides a molecular basis for the maintenance of t 
cell survival, expansion of t cells and increased secre-
tion of growth factors, which may contribute to the 
protective effect in the CnS28. beers et al.29 showed 
in a model of chronic neurodegeneration that activa-
tion of glia did not predict glial function, and that the 
presence of CD4+ t cells induced neuroprotection by 
modulating the trophic/cytotoxic balance of glia. 
There are no studies published in the literature 
concerning OX40 in AlS. The present study showed 
that sOX40 levels in serum of patients with AlS were 
decreased compared with controls. banerjee et al.30 in-
vestigated the role of t cell immunity in human G93A 
superoxide dismutase 1 (SOD1) transgenic mice and 
in AlS patients, and demonstrated dysfunction and 
deficits of t cells. because OX40 can influence t 
cells, which have a potential protective role in im-
mune/inflammatory reactions in the CnS, it cannot 
be excluded that this cytokine is implicated in neuro-
degeneration in AlS. in conditions associated with 
the activation of immune/inflammatory mechanisms, 
the sOX40 levels would be increased. Contrary, the 
present study showed that this cytokine levels were 
decreased in serum of patients with AlS compared to 
controls. it cannot be excluded that the lower serum 
level of this cytokine may be the result of its higher 
activity in the immune-inflammatory process within 
the CnS. it was observed that the study parameter of 
OX40 serum concentration need not reflect its con-
centration within the organs31.
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Sažetak
OX40 tOPlJiV u Serumu KOD bOleSniKA S AmiOtrOFiČnOm lAterAlnOm SKlerOZOm
J. Iłżecka
SummAry – Amiotrofična lateralna skleroza (AlS) je neurodegenerativna bolest. literaturni podaci pokazuju da 
sistemsko aktiviranje imuno sustava ima ulogu kod AlS. OX40 (CD134) pripada obitelji receptora faktora tumorske ne-
kroze (tnF), a izražen je selektivno na aktiviranim t limfocitima. Cilj studije bio je izmjeriti razine OX40 topljivog u se-
rumu (sOX40) kod bolesnika s AlS. u studiju je bilo uključeno 25 bolesnika s AlS i 15 kontrolnih osoba. razine sOX40 
u serumu mjerene su metodom eliSA. rezultati su pokazali da su razine sOX40 značajno snižene u serumu bolesnika s 
AlS u usporedbi s kontrolnim osobama (p=0,05). nije bilo značajne korelacije između serumskih razina sOX40 i klinič-
kih parametara AlS, kao što su težina kliničkog stanja bolesnika s AlS i trajanje bolesti (p>0,05). u zaključku, serumske 
razine sOX40 kod bolesnika s AlS ukazuju na to da bi ovaj citokin mogao biti upleten u patomehanizme ove bolesti.
Ključne riječi: Amiotrofična lateralna skleroza; Neurodegeneracija; Neuroprotekcija; Serum; Topljivi OX40

